


STUDY DESIGN FOR PART A

PART A: SINGLE ASCENDING DOSE

COHORTS A1 THROUGH A8: 8 SUBJECTS PER COHORT^a, RANDOMIZED 3:1 (COMPOUND I:PLACEBO)

COHORT A9: 8 SUBJECTS, OPEN-LABEL


COHORT A10: 28 SUBJECTS, OPEN-LABEL



NOTES: FIGURE NOT DRAWN TO SCALE. COHORTS A1 THROUGH A7 WERE DOSED UNDER FASTED CONDITIONS AND COHORT A8 WAS DOSED UNDER FED CONDITIONS. COHORT A10 WAS DOSED UNDER FED OR FASTED CONDITIONS DEPENDING ON THE TREATMENT SEQUENCE.

^a COHORT A2 ENROLLED 9 SUBJECTS.

FIG. 1



q24h: ONCE DAILY

NOTES: FIGURE NOT DRAWN TO SCALE. COHORTS B1 THROUGH B5 WERE DOSED UNDER FASTED CONDITIONS. COHORT B6 WAS DOSED UNDER FED CONDITIONS.


^a COHORT B6 ENROLLED 7 SUBJECTS. DOSING WAS DISCONTINUED AT DAY 6 DUE TO AES RELATED TO DYSTONIA/DYSKINESIA).

FIG. 2

STUDY DESIGN FOR PART C

PART C: DDI STUDY

15 SUBJECTS PER COHORT, OPEN-LABEL



DDI: DRUG-DRUG INTERACTION

NOTES: FIGURE NOT DRAWN TO SCALE. COHORTS C1 AND C2 WERE DOSED UNDER FASTED CONDITIONS

FIG. 3